{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T21:16:14Z","timestamp":1792012574358,"version":"4.4.0"},"reference-count":97,"publisher":"Springer Science and Business Media LLC","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Osteoporos Int"],"published-print":{"date-parts":[[2011,2]]},"DOI":"10.1007\/s00198-010-1453-5","type":"journal-article","created":{"date-parts":[[2010,11,17]],"date-time":"2010-11-17T13:44:45Z","timestamp":1290001485000},"page":"373-390","source":"Crossref","is-referenced-by-count":191,"title":["Subtrochanteric fractures after long-term treatment with bisphosphonates: a European Society on Clinical and Economic Aspects of Osteoporosis and Osteoarthritis, and International Osteoporosis Foundation Working Group Report"],"prefix":"10.1007","volume":"22","author":[{"given":"R.","family":"Rizzoli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"\u00c5kesson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Bouxsein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. A.","family":"Kanis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Napoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Papapoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.-Y.","family":"Reginster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Cooper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2010,11,18]]},"reference":[{"key":"1453_CR1","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1016\/S0140-6736(96)07088-2","volume":"348","author":"DM Black","year":"1996","unstructured":"Black DM, Cummings SR, Karpf DB, Cauley JA, Thompson DE, Nevitt MC, Bauer DC, Genant HK, Haskell WL, Marcus R, Ott SM, Torner JC, Quandt SA, Reiss TF, Ensrud KE (1996) Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 348:1535\u20131541","journal-title":"Lancet"},{"key":"1453_CR2","doi-asserted-by":"crossref","first-page":"2927","DOI":"10.1001\/jama.296.24.2927","volume":"296","author":"DM Black","year":"2006","unstructured":"Black DM, Schwartz AV, Ensrud KE, Cauley JA, Levis S, Quandt SA, Satterfield S, Wallace RB, Bauer DC, Palermo L, Wehren LE, Lombardi A, Santora AC, Cummings SR (2006) Effects of continuing or stopping alendronate after 5\u00a0years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. JAMA 296:2927\u20132938","journal-title":"JAMA"},{"key":"1453_CR3","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa067312","volume":"356","author":"DM Black","year":"2007","unstructured":"Black DM, Delmas PD, Eastell R, Reid IR, Boonen S, Cauley JA, Cosman F, Lakatos P, Leung PC, Man Z, Mautalen C, Mesenbrink P, Hu H, Caminis J, Tong K, Rosario-Jansen T, Krasnow J, Hue TF, Sellmeyer D, Eriksen EF, Cummings SR (2007) Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 356:1809\u20131822","journal-title":"N Engl J Med"},{"key":"1453_CR4","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1359\/JBMR.040325","volume":"19","author":"CH Chesnut III","year":"2004","unstructured":"Chesnut CH III, Skag A, Christiansen C, Recker R, Stakkestad JA, Hoiseth A, Felsenberg D, Huss H, Gilbride J, Schimmer RC, Delmas PD (2004) Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res 19:1241\u20131249","journal-title":"J Bone Miner Res"},{"key":"1453_CR5","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1001\/jama.280.24.2077","volume":"280","author":"SR Cummings","year":"1998","unstructured":"Cummings SR, Black DM, Thompson DE, Applegate WB, Barrett-Connor E, Musliner TA, Palermo L, Prineas R, Rubin SM, Scott JC, Vogt T, Wallace R, Yates AJ, LaCroix AZ (1998) Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA 280:2077\u20132082","journal-title":"JAMA"},{"key":"1453_CR6","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1001\/jama.282.14.1344","volume":"282","author":"ST Harris","year":"1999","unstructured":"Harris ST, Watts NB, Genant HK, McKeever CD, Hangartner T, Keller M, Chesnut CH III, Brown J, Eriksen EF, Hoseyni MS, Axelrod DW, Miller PD (1999) Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. JAMA 282:1344\u20131352","journal-title":"JAMA"},{"key":"1453_CR7","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1056\/NEJMoa074941","volume":"357","author":"KW Lyles","year":"2007","unstructured":"Lyles KW, Colon-Emeric CS, Magaziner JS, Adachi JD, Pieper CF, Mautalen C, Hyldstrup L, Recknor C, Nordsletten L, Moore KA, Lavecchia C, Zhang J, Mesenbrink P, Hodgson PK, Abrams K, Orloff JJ, Horowitz Z, Eriksen EF, Boonen S (2007) Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med 357:1799\u20131809","journal-title":"N Engl J Med"},{"key":"1453_CR8","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s001980050010","volume":"11","author":"J Reginster","year":"2000","unstructured":"Reginster J, Minne HW, Sorensen OH, Hooper M, Roux C, Brandi ML, Lund B, Ethgen D, Pack S, Roumagnac I, Eastell R (2000) Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Osteoporos Int 11:83\u201391","journal-title":"Osteoporos Int"},{"key":"1453_CR9","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/S8756-3282(02)00946-8","volume":"32","author":"OH Sorensen","year":"2003","unstructured":"Sorensen OH, Crawford GM, Mulder H, Hosking DJ, Gennari C, Mellstrom D, Pack S, Wenderoth D, Cooper C, Reginster JY (2003) Long-term efficacy of risedronate: a 5-year placebo-controlled clinical experience. Bone 32:120\u2013126","journal-title":"Bone"},{"key":"1453_CR10","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1056\/NEJM200102013440503","volume":"344","author":"MR McClung","year":"2001","unstructured":"McClung MR, Geusens P, Miller PD, Zippel H, Bensen WG, Roux C, Adami S, Fogelman I, Diamond T, Eastell R, Meunier PJ, Reginster JY (2001) Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N Engl J Med 344:333\u2013340","journal-title":"N Engl J Med"},{"key":"1453_CR11","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1016\/S0140-6736(09)60250-6","volume":"373","author":"DM Reid","year":"2009","unstructured":"Reid DM, Devogelaer JP, Saag K, Roux C, Lau CS, Reginster JY, Papanastasiou P, Ferreira A, Hartl F, Fashola T, Mesenbrink P, Sambrook PN (2009) Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomised controlled trial. Lancet 373:1253\u20131263","journal-title":"Lancet"},{"key":"1453_CR12","doi-asserted-by":"crossref","first-page":"241","DOI":"10.2165\/00024677-200201040-00006","volume":"1","author":"JP Devogelaer","year":"2002","unstructured":"Devogelaer JP (2002) Modern therapy for Paget\u2019s disease of bone: focus on bisphosphonates. Treat Endocrinol 1:241\u2013257","journal-title":"Treat Endocrinol"},{"key":"1453_CR13","doi-asserted-by":"crossref","first-page":"92","DOI":"10.3816\/SCT.2007.n.003","volume":"4","author":"A Lipton","year":"2007","unstructured":"Lipton A (2007) Treatment of bone metastases and bone pain with bisphosphonates. Support Cancer Ther 4:92\u2013100","journal-title":"Support Cancer Ther"},{"key":"1453_CR14","first-page":"27","volume":"3","author":"TJ Polascik","year":"2009","unstructured":"Polascik TJ (2009) Bisphosphonates in oncology: evidence for the prevention of skeletal events in patients with bone metastases. Drug Des Devel Ther 3:27\u201340","journal-title":"Drug Des Devel Ther"},{"key":"1453_CR15","volume-title":"Bonviva summary of product characteristics","author":"Roche Registration Limited","year":"2009","unstructured":"Roche Registration Limited (2009) Bonviva summary of product characteristics. Roche Registration, Hertfordshire"},{"key":"1453_CR16","volume-title":"Fosamax summary of product characteristics","author":"Merck SaDL","year":"2007","unstructured":"Merck SaDL (2007) Fosamax summary of product characteristics. Merck SaDL, Hertfordshire"},{"key":"1453_CR17","volume-title":"Actonel summary of product characteristics","author":"Procter & Gamble Pharmaceuticals","year":"2007","unstructured":"Procter & Gamble Pharmaceuticals (2007) Actonel summary of product characteristics. Procter & Gamble Pharmaceuticals, Weybridge"},{"key":"1453_CR18","unstructured":"US Food and Drug Administration (FDA) (2009) Drug safety newsletter. Volume 2, Number 2. http:\/\/www.fda.gov\/Drugs\/DrugSafety\/DrugSafetyNewsletter\/default.htm . Accessed 23 Sep 2010"},{"key":"1453_CR19","doi-asserted-by":"crossref","first-page":"2278","DOI":"10.1056\/NEJMp068157","volume":"355","author":"JP Bilezikian","year":"2006","unstructured":"Bilezikian JP (2006) Osteonecrosis of the jaw\u2014do bisphosphonates pose a risk? N Engl J Med 355:2278\u20132281","journal-title":"N Engl J Med"},{"key":"1453_CR20","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1016\/j.bone.2008.01.003","volume":"42","author":"R Rizzoli","year":"2008","unstructured":"Rizzoli R, Burlet N, Cahall D, Delmas PD, Eriksen EF, Felsenberg D, Grbic J, Jontell M, Landesberg R, Laslop A, Wollenhaupt M, Papapoulos S, Sezer O, Sprafka M, Reginster JY (2008) Osteonecrosis of the jaw and bisphosphonate treatment for osteoporosis. Bone 42:841\u2013847","journal-title":"Bone"},{"key":"1453_CR21","volume-title":"Aclasta summary of product characteristics","author":"Novartis Europharm Limited","year":"2009","unstructured":"Novartis Europharm Limited (2009) Aclasta summary of product characteristics. Novartis Europharm, Horsham"},{"key":"1453_CR22","volume-title":"Fosavance summary of product characteristics","author":"Merck Sharp & Dohme Limited","year":"2009","unstructured":"Merck Sharp & Dohme Limited (2009) Fosavance summary of product characteristics. Merck Sharp & Dohme, Hertfordshire"},{"key":"1453_CR23","volume-title":"Boniva (ibandronate sodium) injection prescribing information","author":"Roche Pharmaceuticals","year":"2009","unstructured":"Roche Pharmaceuticals (2009) Boniva (ibandronate sodium) injection prescribing information. Roche Pharmaceuticals, Nutley"},{"key":"1453_CR24","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1007\/BF00305532","volume":"54","author":"N Guanabens","year":"1994","unstructured":"Guanabens N, Peris P, Monegal A, Pons F, Collado A, Munoz-Gomez J (1994) Lower extremity stress fractures during intermittent cyclical etidronate treatment for osteoporosis. Calcif Tissue Int 54:431\u2013434","journal-title":"Calcif Tissue Int"},{"key":"1453_CR25","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/s00223-009-9263-5","volume":"85","author":"R Armamento-Villareal","year":"2009","unstructured":"Armamento-Villareal R, Napoli N, Diemer K, Watkins M, Civitelli R, Teitelbaum S, Novack D (2009) Bone turnover in bone biopsies of patients with low-energy cortical fractures receiving bisphosphonates: a case series. Calcif Tissue Int 85:37\u201344","journal-title":"Calcif Tissue Int"},{"key":"1453_CR26","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1302\/0301-620X.89B3.18146","volume":"89","author":"SK Goh","year":"2007","unstructured":"Goh SK, Yang KY, Koh JS, Wong MK, Chua SY, Chua DT, Howe TS (2007) Subtrochanteric insufficiency fractures in patients on alendronate therapy: a caution. J Bone Joint Surg Br 89:349\u2013353","journal-title":"J Bone Joint Surg Br"},{"key":"1453_CR27","doi-asserted-by":"crossref","first-page":"775","DOI":"10.2165\/00002018-200932090-00002","volume":"32","author":"K Ing-Lorenzini","year":"2009","unstructured":"Ing-Lorenzini K, Desmeules J, Plachta O, Suva D, Dayer P, Peter R (2009) Low-energy femoral fractures associated with the long-term use of bisphosphonates: a case series from a Swiss university hospital. Drug Saf 32:775\u2013785","journal-title":"Drug Saf"},{"key":"1453_CR28","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.injury.2007.08.036","volume":"39","author":"EB Kwek","year":"2008","unstructured":"Kwek EB, Goh SK, Koh JS, Png MA, Howe TS (2008) An emerging pattern of subtrochanteric stress fractures: a long-term complication of alendronate therapy? Injury 39:224\u2013231","journal-title":"Injury"},{"key":"1453_CR29","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1007\/s00198-008-0805-x","volume":"20","author":"BA Lenart","year":"2009","unstructured":"Lenart BA, Neviaser AS, Lyman S, Chang CC, Edobor-Osula F, Steele B, van der Meulen MC, Lorich DG, Lane JM (2009) Association of low-energy femoral fractures with prolonged bisphosphonate use: a case control study. Osteoporos Int 20:1353\u20131362","journal-title":"Osteoporos Int"},{"key":"1453_CR30","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1097\/BOT.0b013e318172841c","volume":"22","author":"AS Neviaser","year":"2008","unstructured":"Neviaser AS, Lane JM, Lenart BA, Edobor-Osula F, Lorich DG (2008) Low-energy femoral shaft fractures associated with alendronate use. J Orthop Trauma 22:346\u2013350","journal-title":"J Orthop Trauma"},{"key":"1453_CR31","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1210\/jc.2004-0952","volume":"90","author":"CV Odvina","year":"2005","unstructured":"Odvina CV, Zerwekh JE, Rao DS, Maalouf N, Gottschalk FA, Pak CY (2005) Severely suppressed bone turnover: a potential complication of alendronate therapy. J Clin Endocrinol Metab 90:1294\u20131301","journal-title":"J Clin Endocrinol Metab"},{"key":"1453_CR32","first-page":"555","volume":"122","author":"JW Fielding","year":"1966","unstructured":"Fielding JW, Magliato HJ (1966) Subtrochanteric fractures. Surg Gynecol Obstet 122:555\u2013560","journal-title":"Surg Gynecol Obstet"},{"key":"1453_CR33","unstructured":"Muller ME, Nazarian S, Koch P, Schatzker J (1990) The AO classification of long bones. http:\/\/aofoundation.com\/AOFileServer\/PortalFiles?FilePath=\/Extranet\/en\/_att\/wor\/act\/fracture_classif\/mueller_ao_class.pdf . Accessed 23 Sep 2010"},{"key":"1453_CR34","doi-asserted-by":"crossref","first-page":"300","DOI":"10.2106\/00004623-197860030-00004","volume":"60","author":"F Seinsheimer","year":"1978","unstructured":"Seinsheimer F (1978) Subtrochanteric fractures of the femur. J Bone Joint Surg Am 60:300\u2013306","journal-title":"J Bone Joint Surg Am"},{"key":"1453_CR35","unstructured":"Black DM, Genant HK, Bucci-Rechtweg C, Bauer DC, Mesenbrink PG, Palermo L, Nusgarten L, Eastell R (2009) Does zoledronic acid increase risk of atypical subtrochanteric femoral shaft fractures? Results from the HORIZON-PFT. J Bone Miner Res 24 (Suppl 1). http:\/\/www.asbmr.org\/Meetings\/AnnualMeeting\/AbstractDetail.aspx?aid=918d35dd-6a3d-43f6-b35f-b484a15b81cf . Accessed 23 Sep 2010"},{"key":"1453_CR36","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.pmrj.2009.11.007","volume":"2","author":"RD Bunning","year":"2010","unstructured":"Bunning RD, Rentfro RJ, Jelinek JS (2010) Low-energy femoral fractures associated with long-term bisphosphonate use in a rehabilitation setting: a case series. PM&R 2:76\u201380","journal-title":"PM&R"},{"key":"1453_CR37","doi-asserted-by":"crossref","first-page":"2556","DOI":"10.2106\/JBJS.H.01774","volume":"91","author":"CM Capeci","year":"2009","unstructured":"Capeci CM, Tejwani NC (2009) Bilateral low-energy simultaneous or sequential femoral fractures in patients on long-term alendronate therapy. J Bone Joint Surg Am 91:2556\u20132561","journal-title":"J Bone Joint Surg Am"},{"key":"1453_CR38","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1097\/BOT.0b013e3181b6499b","volume":"24","author":"JS Koh","year":"2010","unstructured":"Koh JS, Goh SK, Png MA, Kwek EB, Howe TS (2010) Femoral cortical stress lesions in long-term bisphosphonate therapy: a herald of impending fracture? J Orthop Trauma 24:75\u201381","journal-title":"J Orthop Trauma"},{"key":"1453_CR39","doi-asserted-by":"crossref","first-page":"2948","DOI":"10.1210\/jc.2007-2803","volume":"93","author":"M Visekruna","year":"2008","unstructured":"Visekruna M, Wilson D, McKiernan FE (2008) Severely suppressed bone turnover and atypical skeletal fragility. J Clin Endocrinol Metab 93:2948\u20132952","journal-title":"J Clin Endocrinol Metab"},{"key":"1453_CR40","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1056\/NEJMc080861","volume":"359","author":"EB Kwek","year":"2008","unstructured":"Kwek EB, Koh JS, Howe TS (2008) More on atypical fractures of the femoral diaphysis. N Engl J Med 359:316\u2013317","journal-title":"N Engl J Med"},{"key":"1453_CR41","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1056\/NEJMc0707493","volume":"358","author":"BA Lenart","year":"2008","unstructured":"Lenart BA, Lorich DG, Lane JM (2008) Atypical fractures of the femoral diaphysis in postmenopausal women taking alendronate. N Engl J Med 358:1304\u20131306","journal-title":"N Engl J Med"},{"key":"1453_CR42","author":"F Leung","year":"2010","unstructured":"Leung F, Lau T-W, To M, Luk K-K, Kung A (2010) Atypical femoral diaphyseal and subtrochanteric fractures and their association with bisphosphonates. BMJ Case Reports. doi: 10.1136\/bcr.10.2008.1073","journal-title":"BMJ Case Reports"},{"key":"1453_CR43","first-page":"70","volume":"16","author":"EA Brandser","year":"1996","unstructured":"Brandser EA, Buckwalter JA (1996) Imaging studies for diagnosing stress and insufficiency fractures. Iowa Orthop J 16:70\u201378","journal-title":"Iowa Orthop J"},{"key":"1453_CR44","doi-asserted-by":"crossref","first-page":"459","DOI":"10.3109\/17453679909000981","volume":"70","author":"K Lunsjo","year":"1999","unstructured":"Lunsjo K, Ceder L, Tidermark J, Hamberg P, Larsson BE, Ragnarsson B, Knebel RW, Allvin I, Hjalmars K, Norberg S, Fornander P, Hauggaard A, Stigsson L (1999) Extramedullary fixation of 107 subtrochanteric fractures: a randomized multicenter trial of the Medoff sliding plate versus 3 other screw-plate systems. Acta Orthop Scand 70:459\u2013466","journal-title":"Acta Orthop Scand"},{"key":"1453_CR45","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1097\/00003086-199003000-00034","volume":"252","author":"GP Whitelaw","year":"1990","unstructured":"Whitelaw GP, Segal D, Sanzone CF, Ober NS, Hadley N (1990) Unstable intertrochanteric\/subtrochanteric fractures of the femur. Clin Orthop Relat Res 252:238\u2013245","journal-title":"Clin Orthop Relat Res"},{"key":"1453_CR46","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1007\/s00198-009-0962-6","volume":"21","author":"JW Nieves","year":"2010","unstructured":"Nieves JW, Bilezikian JP, Lane JM, Einhorn TA, Wang Y, Steinbuch M, Cosman F (2010) Fragility fractures of the hip and femur: incidence and patient characteristics. Osteoporos Int 21:299\u2013408","journal-title":"Osteoporos Int"},{"key":"1453_CR47","doi-asserted-by":"crossref","first-page":"S68","DOI":"10.1016\/j.bone.2009.01.172","volume":"44","author":"DA Glennon","year":"2009","unstructured":"Glennon DA (2009) Subtrochanteric stress fractures in six patients on long term bisphosphonate therapy: a case series. Bone 44:S68\u2013S98","journal-title":"Bone"},{"key":"1453_CR48","unstructured":"National Institute for Health and Clinical Excellence (2010) Final appraisal determination. Alendronate, etidronate, risedronate, raloxifene and strontium ranelate for the primary prevention of osteoporotic fragility fractures in postmenopausal women (amended). NICE technology appraisal guidance 160 (amended). http:\/\/www.nice.org.uk\/nicemedia\/pdf\/TA160guidance.pdf . Accessed 23 Sep 2010"},{"key":"1453_CR49","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1007\/s00198-006-0172-4","volume":"17","author":"O Johnell","year":"2006","unstructured":"Johnell O, Kanis JA (2006) An estimate of the worldwide prevalence and disability associated with osteoporotic fractures. Osteoporos Int 17:1726\u20131733","journal-title":"Osteoporos Int"},{"key":"1453_CR50","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.bone.2010.05.019","volume":"47","author":"A Giusti","year":"2010","unstructured":"Giusti A, Hamdy NA, Papapoulos SE (2010) Atypical fractures of the femur and bisphosphonate therapy. A systematic review of case\/case series studies. Bone 47:169\u2013180","journal-title":"Bone"},{"key":"1453_CR51","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1007\/s00068-005-1421-5","volume":"31","author":"G Husada","year":"2005","unstructured":"Husada G, Libberecht K, Peeters T, Populaire J (2005) Bilateral mid-diaphyseal femoral stress fractures in the elderly. Eur J Trauma 31:68\u201371","journal-title":"Eur J Trauma"},{"key":"1453_CR52","first-page":"31","volume":"61","author":"JP Schneider","year":"2006","unstructured":"Schneider JP (2006) Should bisphosphonates be continued indefinitely? An unusual fracture in a healthy woman on long-term alendronate. Geriatrics 61:31\u201333","journal-title":"Geriatrics"},{"key":"1453_CR53","doi-asserted-by":"crossref","first-page":"2048","DOI":"10.1056\/NEJMc062268","volume":"355","author":"R Armamento-Villareal","year":"2006","unstructured":"Armamento-Villareal R, Napoli N, Panwar V, Novack D (2006) Suppressed bone turnover during alendronate therapy for high-turnover osteoporosis. N Engl J Med 355:2048\u20132050","journal-title":"N Engl J Med"},{"key":"1453_CR54","first-page":"485","volume":"13","author":"RK Cheung","year":"2007","unstructured":"Cheung RK, Leung KK, Lee KC, Chow TC (2007) Sequential non-traumatic femoral shaft fractures in a patient on long-term alendronate. Hong Kong Med J 13:485\u2013489","journal-title":"Hong Kong Med J"},{"key":"1453_CR55","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1007\/s00402-007-0373-0","volume":"127","author":"B Demiralp","year":"2007","unstructured":"Demiralp B, Ilgan S, Ozgur KA, Cicek EI, Yildrim D, Erler K (2007) Bilateral femoral insufficiency fractures treated with inflatable intramedullary nails: a case report. Arch Orthop Trauma Surg 127:597\u2013601","journal-title":"Arch Orthop Trauma Surg"},{"key":"1453_CR56","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1007\/BF03346353","volume":"30","author":"P Lee","year":"2007","unstructured":"Lee P, van der Wall H, Seibel MJ (2007) Looking beyond low bone mineral density: multiple insufficiency fractures in a woman with post-menopausal osteoporosis on alendronate therapy. J Endocrinol Investig 30:590\u2013597","journal-title":"J Endocrinol Investig"},{"key":"1453_CR57","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1080\/17453670710015580","volume":"79","author":"AS Sayed-Noor","year":"2008","unstructured":"Sayed-Noor AS, Sjoden GO (2008) Subtrochanteric displaced insufficiency fracture after long-term alendronate therapy\u2014a case report. Acta Orthop 79:565\u2013567","journal-title":"Acta Orthop"},{"key":"1453_CR58","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1111\/j.1365-2265.2009.03581.x","volume":"72","author":"CV Odvina","year":"2009","unstructured":"Odvina CV, Levy S, Rao S, Zerwekh JE, Sudhaker RD (2009) Unusual mid-shaft fractures during long term bisphosphonate therapy. Clin Endocrinol (Oxf) 72:161\u2013168","journal-title":"Clin Endocrinol (Oxf)"},{"key":"1453_CR59","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1093\/ageing\/afp106","volume":"38","author":"T Ali","year":"2009","unstructured":"Ali T, Jay RH (2009) Spontaneous femoral shaft fracture after long-term alendronate. Age Ageing 38:625\u2013626","journal-title":"Age Ageing"},{"key":"1453_CR60","doi-asserted-by":"crossref","first-page":"607","DOI":"10.3928\/01477447-20090624-27","volume":"32","author":"MS Goddard","year":"2009","unstructured":"Goddard MS, Reid KR, Johnston JC, Khanuja HS (2009) Atraumatic bilateral femur fracture in long-term bisphosphonate use. Orthopedics 32:607. doi: 10.3928\/01477447-20090624-27","journal-title":"Orthopedics"},{"key":"1453_CR61","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1007\/s11999-009-0725-x","volume":"467","author":"AS Sayed-Noor","year":"2009","unstructured":"Sayed-Noor AS, Sjoden GO (2009) Case reports: two femoral insufficiency fractures after long-term alendronate therapy. Clin Orthop Relat Res 467:1921\u20131926","journal-title":"Clin Orthop Relat Res"},{"key":"1453_CR62","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.1007\/s11999-009-1192-0","volume":"468","author":"K Cermak","year":"2009","unstructured":"Cermak K, Shumelinsky F, Alexiou J, Gebhart MJ (2009) Case reports: subtrochanteric femoral stress fractures after prolonged alendronate therapy. Clin Orthop Relat Res 468:1991\u20131996","journal-title":"Clin Orthop Relat Res"},{"key":"1453_CR63","unstructured":"Bush LA, Chew FS (2009) Subtrochanteric femoral insufficiency fracture in woman on bisphosphonate therapy for glucocorticoid-induced osteoporosis. Radiol Case Rep 4. doi: 1.2484\/rcr.v4i1.261"},{"key":"1453_CR64","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1111\/j.1756-185X.2009.01396.x","volume":"12","author":"JK Lee","year":"2009","unstructured":"Lee JK (2009) Bilateral atypical femoral diaphyseal fractures in a patient treated with alendronate sodium. Int J Rheum Dis 12:149\u2013154","journal-title":"Int J Rheum Dis"},{"key":"1453_CR65","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1007\/s00198-009-0986-y","volume":"21","author":"MH Edwards","year":"2010","unstructured":"Edwards MH, McCrae FC, Young-Min SA (2010) Alendronate-related femoral diaphysis fracture\u2014what should be done to predict and prevent subsequent fracture of the contralateral side? Osteoporos Int 21:701\u2013703","journal-title":"Osteoporos Int"},{"key":"1453_CR66","doi-asserted-by":"crossref","first-page":"413","DOI":"10.3109\/17453670903139914","volume":"80","author":"J Schilcher","year":"2009","unstructured":"Schilcher J, Aspenberg P (2009) Incidence of stress fractures of the femoral shaft in women treated with bisphosphonate. Acta Orthop 80:413\u2013415","journal-title":"Acta Orthop"},{"key":"1453_CR67","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1359\/jbmr.081247","volume":"24","author":"B Abrahamsen","year":"2009","unstructured":"Abrahamsen B, Eiken P, Eastell R (2009) Subtrochanteric and diaphyseal femur fractures in patients treated with alendronate: a register-based national cohort study. J Bone Miner Res 24:1095\u20131102","journal-title":"J Bone Miner Res"},{"key":"1453_CR68","doi-asserted-by":"crossref","first-page":"4118","DOI":"10.1210\/jc.85.11.4118","volume":"85","author":"DM Black","year":"2000","unstructured":"Black DM, Thompson DE, Bauer DC, Ensrud K, Musliner T, Hochberg MC, Nevitt MC, Suryawanshi S, Cummings SR (2000) Fracture risk reduction with alendronate in women with osteoporosis: the Fracture Intervention Trial. FIT Research Group. J Clin Endocrinol Metab 85:4118\u20134124","journal-title":"J Clin Endocrinol Metab"},{"key":"1453_CR69","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1056\/NEJMoa1001086","volume":"362","author":"DM Black","year":"2010","unstructured":"Black DM, Kelly MP, Genant HK, Palermo L, Eastell R, Bucci-Rechtweg C, Cauley J, Leung PC, Boonen S, Santora A, de Papp A, Bauer DC (2010) Bisphosphonates and fractures of the subtrochanteric or diaphyseal femur. N Engl J Med 362:1761\u20131771","journal-title":"N Engl J Med"},{"key":"1453_CR70","unstructured":"Bilezikian J, Klemes A, Silverman S, Cosman F (2009) Subtrochanteric fracture reports coincident with risedronate use. J Bone Miner Res 24(Suppl 1). http:\/\/www.asbmr.org\/Meetings\/AnnualMeeting\/AbstractDetail.aspx?aid=0367cfaa-4d0d-47d8-a57a-ff76098839a2 . Accessed 23 Sep 2010"},{"key":"1453_CR71","first-page":"488","volume":"35","author":"JA Eisman","year":"2008","unstructured":"Eisman JA, Civitelli R, Adami S, Czerwinski E, Recknor C, Prince R, Reginster JY, Zaidi M, Felsenberg D, Hughes C, Mairon N, Masanauskaite D, Reid DM, Delmas PD, Recker RR (2008) Efficacy and tolerability of intravenous ibandronate injections in postmenopausal osteoporosis: 2-year results from the DIVA study. J Rheumatol 35:488\u2013497","journal-title":"J Rheumatol"},{"key":"1453_CR72","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1359\/JBMR.050313","volume":"20","author":"PD Miller","year":"2005","unstructured":"Miller PD, McClung MR, Macovei L, Stakkestad JA, Luckey M, Bonvoisin B, Reginster JY, Recker RR, Hughes C, Lewiecki EM, Felsenberg D, Delmas PD, Kendler DL, Bolognese MA, Mairon N, Cooper C (2005) Monthly oral ibandronate therapy in postmenopausal osteoporosis: 1-year results from the MOBILE study. J Bone Miner Res 20:1315\u20131322","journal-title":"J Bone Miner Res"},{"key":"1453_CR73","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1016\/j.bone.2004.01.008","volume":"34","author":"R Recker","year":"2004","unstructured":"Recker R, Stakkestad JA, Chesnut CH III, Christiansen C, Skag A, Hoiseth A, Ettinger M, Mahoney P, Schimmer RC, Delmas PD (2004) Insufficiently dosed intravenous ibandronate injections are associated with suboptimal antifracture efficacy in postmenopausal osteoporosis. Bone 34:890\u2013899","journal-title":"Bone"},{"key":"1453_CR74","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1185\/030079908X253889","volume":"24","author":"PD Miller","year":"2008","unstructured":"Miller PD, Epstein S, Sedarati F, Reginster JY (2008) Once-monthly oral ibandronate compared with weekly oral alendronate in postmenopausal osteoporosis: results from the head-to-head MOTION study. Curr Med Res Opin 24:207\u2013213","journal-title":"Curr Med Res Opin"},{"key":"1453_CR75","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1007\/s10067-007-0824-6","volume":"27","author":"JA Stakkestad","year":"2008","unstructured":"Stakkestad JA, Lakatos P, Lorenc R, Sedarati F, Neate C, Reginster JY (2008) Monthly oral ibandronate is effective and well tolerated after 3\u00a0years: the MOBILE long-term extension. Clin Rheumatol 27:955\u2013960","journal-title":"Clin Rheumatol"},{"key":"1453_CR76","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.bone.2008.09.011","volume":"44","author":"MR McClung","year":"2009","unstructured":"McClung MR, Bolognese MA, Sedarati F, Recker RR, Miller PD (2009) Efficacy and safety of monthly oral ibandronate in the prevention of postmenopausal bone loss. Bone 44:418\u2013422","journal-title":"Bone"},{"issue":"Suppl 3","key":"1453_CR77","first-page":"494","volume":"68","author":"G Bianchi","year":"2009","unstructured":"Bianchi G, Felsenberg D, Czerwinski E, Reid D, Kenwright A, Burdeska A, Recker R (2009) Efficacy of IV ibandronate is maintained over 5\u00a0years: the DIVA LTE study. Ann Rheum Dis 68(Suppl 3):494","journal-title":"Ann Rheum Dis"},{"key":"1453_CR78","unstructured":"European Medicines Agency (2009) Assessment report for Fosavance. EMEA\/CHMP\/188952\/2009. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Assessment_Report_-_Variation\/human\/000619\/WC500024252.pdf . Accessed 23 Sep 2010"},{"key":"1453_CR79","volume-title":"Fosamax summary of product characteristics","author":"Merck Sharp & Dohme Limited","year":"2010","unstructured":"Merck Sharp & Dohme Limited (2010) Fosamax summary of product characteristics. Merck Sharp & Dohme, Hertfordshire"},{"key":"1453_CR80","volume-title":"EMEA 2010 priorities for drug safety research. Long-term adverse skeletal effects of bisphosphonates. Doc.Ref: EMEA\/493711\/2009 Rev.1","author":"European Medicines Agency","year":"2009","unstructured":"European Medicines Agency (2009) EMEA 2010 priorities for drug safety research. Long-term adverse skeletal effects of bisphosphonates. Doc.Ref: EMEA\/493711\/2009 Rev.1. European Medicines Agency, London"},{"key":"1453_CR81","unstructured":"US Food and Drug Administration (FDA) (2010) FDA drug safety communication: ongoing safety review of oral bisphosphonates and atypical subtrochanteric fractures. http:\/\/www.fda.gov\/Drugs\/DrugSafety\/PostmarketDrugSafetyInformationforPatientsandProviders\/ucm203891.htm . Accessed 23 Sep 2010"},{"key":"1453_CR82","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1359\/jbmr.060701","volume":"21","author":"E Durchschlag","year":"2006","unstructured":"Durchschlag E, Paschalis EP, Zoehrer R, Roschger P, Fratzl P, Recker R, Phipps R, Klaushofer K (2006) Bone material properties in trabecular bone from human iliac crest biopsies after 3\u2013 and 5\u2013year treatment with risedronate. J Bone Miner Res 21:1581\u20131590","journal-title":"J Bone Miner Res"},{"key":"1453_CR83","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1007\/s00198-008-0725-9","volume":"20","author":"AL Boskey","year":"2009","unstructured":"Boskey AL, Spevak L, Weinstein RS (2009) Spectroscopic markers of bone quality in alendronate treated postmenopausal women. Osteoporos Int 20:793\u2013800","journal-title":"Osteoporos Int"},{"key":"1453_CR84","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/B978-0-323-03437-1.50013-0","volume-title":"Osteoporosis and the osteoporosis of rheumatic diseases","author":"CH Turner","year":"2006","unstructured":"Turner CH, Burr DB (2006) Principles of bone biomechanics. In: Lane NE, Sambrook PN (eds) Osteoporosis and the osteoporosis of rheumatic diseases. Mosby Elsevier, Philadelphia, pp 41\u201353"},{"key":"1453_CR85","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/S8756-3282(00)00376-8","volume":"27","author":"GY Boivin","year":"2000","unstructured":"Boivin GY, Chavassieux PM, Santora AC, Yates J, Meunier PJ (2000) Alendronate increases bone strength by increasing the mean degree of mineralization of bone tissue in osteoporotic women. Bone 27:687\u2013694","journal-title":"Bone"},{"key":"1453_CR86","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/S8756-3282(01)00485-9","volume":"29","author":"P Roschger","year":"2001","unstructured":"Roschger P, Rinnerthaler S, Yates J, Rodan GA, Fratzl P, Klaushofer K (2001) Alendronate increases degree and uniformity of mineralization in cancellous bone and decreases the porosity in cortical bone of osteoporotic women. Bone 29:185\u2013191","journal-title":"Bone"},{"key":"1453_CR87","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1359\/jbmr.070720","volume":"22","author":"MR Allen","year":"2007","unstructured":"Allen MR, Burr DB (2007) Three years of alendronate treatment results in similar levels of vertebral microdamage as after one year of treatment. J Bone Miner Res 22:1759\u20131765","journal-title":"J Bone Miner Res"},{"key":"1453_CR88","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1016\/j.bone.2006.04.028","volume":"39","author":"MR Allen","year":"2006","unstructured":"Allen MR, Iwata K, Phipps R, Burr DB (2006) Alterations in canine vertebral bone turnover, microdamage accumulation, and biomechanical properties following 1\u2013year treatment with clinical treatment doses of risedronate or alendronate. Bone 39:872\u2013879","journal-title":"Bone"},{"key":"1453_CR89","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1007\/s00223-008-9131-8","volume":"82","author":"MR Allen","year":"2008","unstructured":"Allen MR, Reinwald S, Burr DB (2008) Alendronate reduces bone toughness of ribs without significantly increasing microdamage accumulation in dogs following 3\u00a0years of daily treatment. Calcif Tissue Int 82:354\u2013360","journal-title":"Calcif Tissue Int"},{"issue":"Suppl","key":"1453_CR90","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.bone.2005.12.023","volume":"38","author":"K Iwata","year":"2006","unstructured":"Iwata K, Allen MR, Phipps R, Burr DB (2006) Microcrack initiation occurs more easily in vertebrae from beagles treated with alendronate than with risedronate. Bone 38(Suppl):42","journal-title":"Bone"},{"key":"1453_CR91","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.1359\/jbmr.2002.17.12.2237","volume":"17","author":"Y Cao","year":"2002","unstructured":"Cao Y, Mori S, Mashiba T, Westmore MS, Ma L, Sato M, Akiyama T, Shi L, Komatsubara S, Miyamoto K, Norimatsu H (2002) Raloxifene, estrogen, and alendronate affect the processes of fracture repair differently in ovariectomized rats. J Bone Miner Res 17:2237\u20132246","journal-title":"J Bone Miner Res"},{"key":"1453_CR92","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1138\/20070271","volume":"4","author":"MM MacDonald","year":"2007","unstructured":"MacDonald MM, Schindeler A, Little DG (2007) Bisphosphonate treatment and fracture repair. BoneKey 4:236\u2013251","journal-title":"BoneKey"},{"key":"1453_CR93","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1016\/j.bone.2010.02.030","volume":"46","author":"MD Martinez","year":"2010","unstructured":"Martinez MD, Schmid GJ, McKenzie JA, Ornitz DM, Silva MJ (2010) Healing of non\u2013displaced fractures produced by fatigue loading of the mouse ulna. Bone 46:1604\u20131612","journal-title":"Bone"},{"key":"1453_CR94","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1359\/jbmr.090408","volume":"24","author":"MP Somford","year":"2009","unstructured":"Somford MP, Draijer FW, Thomassen BJ, Chavassieux PM, Boivin G, Papapoulos SE (2009) Bilateral fractures of the femur diaphysis in a patient with rheumatoid arthritis on long-term treatment with alendronate: clues to the mechanism of increased bone fragility. J Bone Miner Res 24:1736\u20131740","journal-title":"J Bone Miner Res"},{"key":"1453_CR95","doi-asserted-by":"crossref","first-page":"iv33","DOI":"10.1093\/rheumatology\/kei059","volume":"44","author":"TW O\u2019Neill","year":"2005","unstructured":"O\u2019Neill TW (2005) Looking back: developments in our understanding of the occurrence, aetiology and prognosis of osteoporosis over the last 50\u00a0years. Rheumatology (Oxford) 44:iv33\u2013iv35","journal-title":"Rheumatology (Oxford)"},{"key":"1453_CR96","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1007\/s00198-008-0712-1","volume":"19","author":"JA Kanis","year":"2008","unstructured":"Kanis JA, McCloskey EV, Johansson H, Strom O, Borgstrom F, Oden A (2008) Case finding for the management of osteoporosis with FRAX\u2014assessment and intervention thresholds for the UK. Osteoporos Int 19:1395\u20131408","journal-title":"Osteoporos Int"},{"key":"1453_CR97","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.bone.2004.08.018","volume":"36","author":"JA Kanis","year":"2005","unstructured":"Kanis JA, Borgstrom F, Zethraeus N, Johnell O, Oden A, Jonsson B (2005) Intervention thresholds for osteoporosis in the UK. Bone 36:22\u201332","journal-title":"Bone"}],"container-title":["Osteoporosis International"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.springerlink.com\/index\/pdf\/10.1007\/s00198-010-1453-5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,4]],"date-time":"2023-06-04T06:48:55Z","timestamp":1685861335000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00198-010-1453-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,11,18]]},"references-count":97,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2011,2]]}},"alternative-id":["1453"],"URL":"https:\/\/doi.org\/10.1007\/s00198-010-1453-5","relation":{},"ISSN":["0937-941X","1433-2965"],"issn-type":[{"value":"0937-941X","type":"print"},{"value":"1433-2965","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,11,18]]}}}